Fate Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Fate Therapeutics's estimated annual revenue is currently $131.1M per year.
- Fate Therapeutics's estimated revenue per employee is $217,000
- Fate Therapeutics's total funding is $1.2B.
- Fate Therapeutics has 604 Employees.
- Fate Therapeutics grew their employee count by 53% last year.
Fate Therapeutics Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Fate Therapeutics?
Fate Therapeutics is applying leading expertise in stem cell biology and conventional drug discovery to develop small molecule and biologic drugs that: 1) activate stem cells in the body to stimulate healing and repair or block cancer growth; and 2) create and differentiate "pharmaceutical grade" iPS cells to enable their use in drug discovery and development, disease modeling, and eventually personalized cell therapies. The Company's approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.keywords:N/A
Number of Employees
Employee Growth %
Fate Therapeutics News
Fate Therapeutics, Inc. (NASDAQ:FATE) Insider Yu-Waye Chu Sells 4,062 Shares. Posted by admin on Apr 21st, 2022. Share on Twitter Share on Facebook Share on...
About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class...
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Recommendation of Buy by Brokerages. Posted by admin on Apr 11th, 2022.
At the cutting edge of oncology research, biotechs like Fate Therapeutics are looking for ways to craft next-gen cell therapies without relying on patients’ own cells. An early peek at the company’s clinical data looks promising, but will iffy durability results prove a ...
Location: San Diego, California. Solution/product: Fate develops stem cell modulators. Its lead drug, ProHema, uses a small molecule (FT1050) to modulate hematopoietic stem cells (HSC), or blood-forming cells, that are transplanted to restore cells destroyed during intensive chemotherapy, radia ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|